Teva Pharmaceutical Industries Limited and Bausch Health Companies Inc.: A Detailed Gross Profit Analysis

Teva vs. Bausch: A Decade of Profit Trends

__timestampBausch Health Companies Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014600890000011056000000
Thursday, January 1, 2015785380000011356000000
Friday, January 1, 2016706300000011859000000
Sunday, January 1, 2017617600000010825000000
Monday, January 1, 201860290000008296000000
Tuesday, January 1, 201962510000007536000000
Wednesday, January 1, 202057780000007725000000
Friday, January 1, 202160400000007594000000
Saturday, January 1, 202257600000006973000000
Sunday, January 1, 202361980000007646000000
Monday, January 1, 20248064000000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Gross Profit Trends in Pharmaceuticals

Teva vs. Bausch: A Financial Journey

Over the past decade, Teva Pharmaceutical Industries Limited and Bausch Health Companies Inc. have navigated the turbulent waters of the pharmaceutical industry with varying degrees of success. From 2014 to 2023, Teva's gross profit saw a significant decline of approximately 31%, dropping from a peak in 2016 to a low in 2022. In contrast, Bausch Health's gross profit remained relatively stable, with a modest fluctuation of around 15% over the same period.

This analysis highlights the resilience of Bausch Health, maintaining a steady course despite industry challenges, while Teva faced a more volatile trajectory. The data underscores the importance of strategic adaptability in the pharmaceutical sector, where market dynamics and regulatory changes can significantly impact financial outcomes. As we look to the future, these trends offer valuable insights for investors and industry stakeholders alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025